Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For phenylketonuria (PKU). Sold as Palynziq. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Pegvaliase-Pqpz (sold as Palynziq), first approved May 24, 2018, with 4 new uses approved and 0 published complete response letters.
First approved: May 24, 2018
Applications: 1
New uses approved: 4
Complete response letters: 0
Medicare spending, 2025: $27.8M
Orphan exclusivity until: Feb 27, 2033
First approved in the EU: May 3, 2019
First approved in Japan: Mar 27, 2023
Safety program: REMS
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 58 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Palynziq, new ingredientDrugs with a new active ingredient indicated for the treatment of phenylketonuria. · BioMarin Pharmaceutical Japan K.K. · Mar 27, 2023
Safety Programs (REMS)
FDA requires these when a drug's risks need more than a label: training, enrollment or extra checks before it is prescribed or dispensed
Program
Updated
Palynziq REMSRestricted: prescribers, pharmacies or patients must be certified or enrolled
Mar 20, 2026
Clinical Trials
5 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA